BioStock: Funding in focus for WntResearch

The cancer therapy company WntResearch entered 2023 with a strengthened cash position after a successful share issue that provided approximately 26.5 MSEK. Recently, the company also announced that warrants of series TO5 were exercised to approximately 92.2 per cent. This adds another 10.6 MSEK to the company. BioStock spoke to CEO Pernilla Sandwall to find out more about the latest quarter and the way forward for the company.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/05/funding-in-focus-for-wntresearch/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se